[go: up one dir, main page]

AR108926A1 - Moduladores de cot y sus métodos de uso - Google Patents

Moduladores de cot y sus métodos de uso

Info

Publication number
AR108926A1
AR108926A1 ARP170101815A ARP170101815A AR108926A1 AR 108926 A1 AR108926 A1 AR 108926A1 AR P170101815 A ARP170101815 A AR P170101815A AR P170101815 A ARP170101815 A AR P170101815A AR 108926 A1 AR108926 A1 AR 108926A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
heteroaryl
cycloalkyl
aryl
Prior art date
Application number
ARP170101815A
Other languages
English (en)
Inventor
Nathan E Wright
William J Watkins
James G Taylor
Neil H Squires
Gary Phillips
John O Link
Musong Kim
Chien Chou
- Balan Gayatri Hung
Thorsten A Kirschberg
Roland D Saito
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR108926A1 publication Critical patent/AR108926A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción se refiere en general a compuestos derivados de quinazolina como moduladores de Cot (cancer Osaka thyroid) y sus métodos de uso y su fabricación. Reivindicación 1: Un compuesto de la fórmula (1), en donde R¹ es alquilo C₁₋₉, cicloalquilo C₃₋₁₅, heterociclilo, heteroarilo o arilo C₆₋₁₀; en donde cada alquilo C₁₋₉, cicloalquilo C₃₋₁₅, heterociclilo, heteroarilo y arilo C₆₋₁₀ puede estar opcionalmente sustituido con uno a cuatro Z¹; R² es hidrógeno, -C(O)-R⁷, -C(O)O-R⁷, -C(O)N(R⁷)₂ o alquilo C₁₋₉; R³ es heterociclilo o heteroarilo; en donde cada heterociclilo o heteroarilo está opcionalmente sustituido con uno a cuatro Z³; R⁴ es arilo, heterociclilo o heteroarilo; en donde cada arilo, heterociclilo o heteroarilo está opcionalmente sustituido con uno a cuatro Z⁴; R⁵ es hidrógeno, halo, ciano, -NO₂, -O-R⁷, -N(R⁸)(R⁹), -S(O)-R⁷, -S(O)₂R⁷, -S(O)₂N(R⁷)₂, -C(O)R⁷, -OC(O)-R⁷, -C(O)O-R⁷, -OC(O)O-R⁷, -OC(O)N(R¹⁰)(R¹¹), -C(O)N(R⁷)₂, -N(R⁷)C(O)(R⁷), alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, alquil C₁₋₉-tio, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo o heteroarilo; en donde cada alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, alquil C₁₋₉-tio, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo y heteroarilo puede estar opcionalmente sustituido con uno a cuatro Z⁵; R⁶ es hidrógeno, -C(O)-R⁷, -C(O)O-R⁷, -C(O)N(R⁷)₂, alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo o heteroarilo; en donde cada alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo y heteroarilo puede estar opcionalmente sustituido con uno a cuatro Z⁶; cada R⁷ es, de modo independiente, hidrógeno, alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo o heteroarilo; en donde cada alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo y heteroarilo puede estar opcionalmente sustituido con uno a cuatro Z⁷; R⁸ y R⁹ en cada aparición son, de modo independiente, hidrógeno, -S(O)₂R¹⁰, -C(O)-R¹⁰, -C(O)O-R¹⁰, -C(O)N(R¹⁰)(R¹¹), alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo o heteroarilo; en donde cada alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo o heteroarilo puede estar opcionalmente sustituido con uno a cuatro Z⁸; R¹⁰ y R¹¹ en cada aparición son, de modo independiente, hidrógeno, alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo o heteroarilo, en donde cada alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo y heteroarilo está opcionalmente sustituido con uno a cuatro Z¹ᵇ; cada Z¹, Z³, Z⁴, Z⁵, Z⁶, Z⁷ y Z⁸ es, de modo independiente, hidrógeno, oxo, halo, -NO₂, -N₃, ciano, tioxo, alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₅, haloalquilo C₁₋₈, arilo, heteroarilo, heterociclilo, -O-R¹², -C(O)-R¹², -C(O)O-R¹², -C(O)-N(R¹³)(R¹⁴), -N(R¹³)(R¹⁴), -N(R¹³)₂(R¹⁴)⁺, -N(R¹²)C(O)-R¹², -N(R¹²)C(O)O-R¹², -N(R¹²)C(O)N(R¹³)(R¹⁴), -N(R¹²)S(O)₂(R¹²), -NR¹²S(O)₂N(R¹³)(R¹⁴), -NR¹²S(O)₂O(R¹²), -OC(O)R¹², -OC(O)-N(R¹³)(R¹⁴), -P(O)(OR¹²)₂, -OP(O)(OR¹²)₂, -CH₂P(O)(OR¹²)₂, -OCH₂P(O)(OR¹²)₂, -C(O)OCH₂P(O)(OR¹²)₂, -P(O)(R¹²)(OR¹²), -OP(O)(R¹²)(OR¹²), -CH₂P(O)(R¹²)(OR¹²), -OCH₂P(O)(R¹²)(OR¹²), -C(O)OCH₂P(O)(R¹²)(OR¹²), -P(O)(N(R¹²)₂)₂, -OP(O)(N(R¹²)₂)₂, -CH₂P(O)(N(R¹²)₂)₂, -OCH₂P(O)(N(R¹²)₂)₂, -C(O)OCH₂P(O)(N(R¹²)₂)₂, -P(O)(N(R¹²)₂)(OR¹²), OP(O)(N(R¹²)₂)(OR¹²), CH₂P(O)(N(R¹²)₂)(OR¹²), -OCH₂P(O)(N(R¹²)₂)(OR¹²), -C(O)OCH₂P(O)(N(R¹²)₂)(OR¹²), -P(O)(R¹²)(N(R¹²)₂), -OP(O)(R¹²)(N(R¹²)₂), -CH₂P(O)(R¹²)(N(R¹²)₂), -OCH₂P(O)(R¹²)(N(R¹²)₂), -C(O)OCH₂P(O)(R¹²)(N(R¹²)₂), -Si(R¹²)₃, -S-R¹², -S(O)R¹², -S(O)(NH)R¹², -S(O)₂R¹² o -S(O)₂N(R¹³)(R¹⁴); en donde cualquier alquilo, alquenilo, alquinilo, cicloalquilo, haloalquilo, arilo, heteroarilo o heterociclilo está opcionalmente sustituido con uno a cuatro grupos Z¹ᵃ; cada Z¹ᵃ es, de modo independiente, oxo, halo, tioxo, -NO₂, ciano, -N₃, alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₅, haloalquilo C₁₋₈, arilo, heteroarilo, heterociclilo, -O-R¹², -C(O)R¹², -C(O)O-R¹², -C(O)N(R¹³)(R¹⁴), -N(R¹³)(R¹⁴), -N(R¹³)₂(R¹⁴)⁺, -N(R¹²)-C(O)R¹², -N(R¹²)C(O)O(R¹²), -N(R¹²)C(O)N(R¹³)(R¹⁴), -N(R¹²)S(O)₂(R¹²), N(R¹²)S(O)₂-N(R¹³)(R¹⁴), -N(R¹²)S(O)₂O(R¹²), -OC(O)R¹², -OC(O)OR¹², -OC(O)-N(R¹³)(R¹⁴), -Si(R¹²)₃, -S-R¹², -S(O)R¹², -S(O)(NH)R¹², -S(O)₂R¹² o -S(O)₂N(R¹³)(R¹⁴); en donde cualquier alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo o heterociclilo está opcionalmente sustituido con uno a cuatro grupos Z¹ᵇ; cada R¹² es, de modo independiente, hidrógeno, alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₅, arilo, heteroarilo o heterociclilo, en donde cualquier alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo o heterociclilo está opcionalmente sustituido con uno a cuatro grupos Z¹ᵇ; R¹³ y R¹⁴ en cada aparición son cada uno, de modo independiente, hidrógeno, alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₅, arilo, heteroarilo o heterociclilo; en donde cualquier alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo o heterociclilo está opcionalmente sustituido con uno a cuatro grupos Z¹ᵇ o R¹³ y R¹⁴ junto con el nitrógeno al que están unidos forman un heterociclilo, en donde dicho heterociclilo está opcionalmente sustituido con uno a cuatro grupos Z¹ᵇ; cada Z¹ᵇ es, de modo independiente, oxo, tioxo, hidroxi, halo, -NO₂, -N₃, ciano, alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₅, haloalquilo C₁₋₈, arilo, heteroarilo, heterociclilo, -O(alquilo C₁₋₉), -O(alquenilo C₂₋₆), -O(alquinilo C₂₋₆), -O(cicloalquilo C₃₋₁₅), -O(haloalquilo C₁₋₈), -O(arilo), -O(heteroarilo), -O(heterociclilo), -NH₂, -NH(alquilo C₁₋₉), -NH(alquenilo C₂₋₆), -NH(alquinilo C₂₋₆), -NH(cicloalquilo C₃₋₁₅), -NH(haloalquilo C₁₋₈), -NH(arilo), -NH(heteroarilo), -NH(heterociclilo), -N(alquilo C₁₋₉)₂, -N(cicloalquilo C₃₋₁₅)₂, -N(alquenilo C₂₋₆)₂, -N(alquinilo C₂₋₆)₂, -N(cicloalquilo C₃₋₁₅)₂, -N(haloalquilo C₁₋₈)₂, -N(arilo)₂, -N(heteroarilo)₂, -N(heterociclilo)₂, -N(alquil C₁₋₉)(cicloalquilo C₃₋₁₅), -N(alquil C₁₋₉)(alquenilo C₂₋₆), -N(alquil C₁₋₉)(alquinilo C₂₋₆), -N(alquil C₁₋₉)(cicloalquilo C₃₋₁₅), -N(alquil C₁₋₉)(haloalquilo C₁₋₈), -N(alquil C₁₋₉)(arilo), -N(alquil C₁₋₉)(heteroarilo), -N(alquil C₁₋₉)(heterociclilo), -C(O)(alquilo C₁₋₉), -C(O)(alquenilo C₂₋₆), -C(O)(alquinilo C₂₋₆), -C(O)(cicloalquilo C₃₋₁₅), -C(O)(haloalquilo C₁₋₈), -C(O)(arilo), -C(O)(heteroarilo), -C(O)(heterociclilo), -C(O)O(alquilo C₁₋₉), -C(O)O(alquenilo C₂₋₆), -C(O)O(alquinilo C₂₋₆), -C(O)O(cicloalquilo C₃₋₁₅), -C(O)O(haloalquilo C₁₋₈), -C(O)O(arilo), -C(O)O(heteroarilo), -C(O)O(heterociclilo), -C(O)NH₂, -C(O)NH(alquilo C₁₋₉), -C(O)NH(alquenilo C₂₋₆), -C(O)NH(alquinilo C₂₋₆), -C(O)NH(cicloalquilo C₃₋₁₅), -C(O)NH(haloalquilo C₁₋₈), -C(O)NH(arilo), -C(O)NH(heteroarilo), -C(O)NH(heterociclilo), -C(O)N(alquilo C₁₋₉)₂, -C(O)N(cicloalquilo C₃₋₁₅)₂, -C(O)N(alquenilo C₂₋₆)₂, -C(O)N(alquinilo C₂₋₆)₂, -C(O)N(cicloalquilo C₃₋₁₅)₂, -C(O)N(haloalquilo C₁₋₈)₂, -C(O)N(arilo)₂, -C(O)N(heteroarilo)₂, -C(O)N(heterociclilo)₂, -NHC(O)(alquilo C₁₋₉), -NHC(O)(alquenilo C₂₋₆), -NHC(O)(alquinilo C₂₋₆), -NHC(O)(cicloalquilo C₃₋₁₅), -NHC(O)(haloalquilo C₁₋₈), -NHC(O)(arilo), -NHC(O)(heteroarilo), -NHC(O)(heterociclilo), -NHC(O)O(alquilo C₁₋₉), -NHC(O)O(alquenilo C₂₋₆), -NHC(O)O(alquinilo C₂₋₆), -NHC(O)O(cicloalquilo C₃₋₁₅), -NHC(O)O(haloalquilo C₁₋₈), -NHC(O)O(arilo), -NHC(O)O(heteroarilo), -NHC(O)O(heterociclilo), -NHC(O)NH(alquilo C₁₋₉), -NHC(O)NH(alquenilo C₂₋₆), -NHC(O)NH(alquinilo C₂₋₆), -NHC(O)NH(cicloalquilo C₃₋₁₅), -NHC(O)NH(haloalquilo C₁₋₈), -NHC(O)NH(arilo), -NHC(O)NH(heteroarilo), -NHC(O)NH(heterociclilo), -SH, -S(alquilo C₁₋₉), -S(alquenilo C₂₋₆), -S(alquinilo C₂₋₆), -S(cicloalquilo C₃₋₁₅), -S(haloalquilo C₁₋₈), -S(arilo), -S(heteroarilo), -S(heterociclilo), -NHS(O)(alquilo C₁₋₉), -N(alquilo C₁₋₉)(S(O)(alquilo C₁₋₉), -S(O)N(alquilo C₁₋₉)₂, -S(O)(alquilo C₁₋₉), -S(O)(NH)(alquilo C₁₋₉), -S(O)(alquenilo C₂₋₆), -S(O)(alquinilo C₂₋₆), -S(O)(cicloalquilo C₃₋₁₅), -S(O)(haloalquilo C₁₋₈), -S(O)(arilo), -S(O)(heteroarilo), -S(O)(heterociclilo), -S(O)₂(alquilo C₁₋₉), -S(O)₂(alquenilo C₂₋₆), -S(O)₂(alquinilo C₂₋₆), -S(O)₂(cicloalquilo C₃₋₁₅), -S(O)₂(haloalquilo C₁₋₈), -S(O)₂(arilo), -S(O)₂(heteroarilo), -S(O)₂(heterociclilo), -S(O)₂NH(alquilo C₁₋₉) o -S(O)₂N(alquilo C₁₋₉)₂; en donde cualquier alquilo, cicloalquilo, arilo, heteroarilo o heterociclilo está opcionalmente sustituido con uno a cuatro halo, alquilo C₁₋₉, haloalquilo C₁₋₈, -OH, -NH₂, -NH(alquilo C₁₋₉), -NH(cicloalquilo C₃₋₁₅), -NH(haloalquilo C₁₋₈), -NH(arilo), -NH(heteroarilo), -NH(heterociclilo), -N(alquilo C₁₋₉)₂, -N(cicloalquilo C₃₋₁₅)₂, -NHC(O)(cicloalquilo C₃₋₁₅), -NHC(O)(haloalquilo C₁₋₈), -NHC(O)(arilo), -NHC(O)(heteroarilo), -NHC(O)(heterociclilo), -NHC(O)O(alquilo C₁₋₉), -NHC(O)O(alquinilo C₂₋₆), -NHC(O)O(cicloalquilo C₃₋₁₅), -NHC(O)O(haloalquilo C₁₋₈), -NHC(O)O(arilo), -NHC(O)O(heteroarilo), -NHC(O)O(heterociclilo), -NHC(O)NH(alquilo C₁₋₉), -S(O)(NH)(alquilo C₁₋₉), S(O)₂(alquilo C₁₋₉), -S(O)₂(cicloalquilo C₃₋₁₅), -S(O)₂(haloalquilo C₁₋₈), -S(O)₂(arilo), -S(O)₂(heteroarilo), -S(O)₂(heterociclilo), -S(O)₂NH(alquilo C₁₋₉), -S(O)₂N(alquilo C₁₋₉)₂, -O(cicloalquilo C₃₋₁₅), -O(haloalquilo C₁₋₈), -O(arilo), -O(heteroarilo), -O(heterociclilo) u -O(alquilo C₁₋₉); m es 0, 1 ó 2; o una de sus sales, estereoisómeros, mezcla de estereoisómeros o análogos farmacéuticamente aceptables.
ARP170101815A 2016-06-30 2017-06-30 Moduladores de cot y sus métodos de uso AR108926A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662356926P 2016-06-30 2016-06-30

Publications (1)

Publication Number Publication Date
AR108926A1 true AR108926A1 (es) 2018-10-10

Family

ID=59285394

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101815A AR108926A1 (es) 2016-06-30 2017-06-30 Moduladores de cot y sus métodos de uso

Country Status (9)

Country Link
US (2) US10059695B2 (es)
EP (1) EP3478674B1 (es)
JP (2) JP6776378B2 (es)
AR (1) AR108926A1 (es)
AU (1) AU2017289158C1 (es)
CA (1) CA3029457A1 (es)
ES (1) ES2800339T3 (es)
TW (2) TWI644910B (es)
WO (1) WO2018005435A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9815818B2 (en) 2015-07-06 2017-11-14 Gilead Sciences, Inc. Cot modulators and methods of use thereof
EP3456717B1 (en) 2015-07-06 2021-03-17 Gilead Sciences, Inc. 4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
EP3478674B1 (en) 2016-06-30 2020-05-13 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
US20220313700A1 (en) * 2019-02-26 2022-10-06 Cell Response, Inc. Methods for treating map3k8 positive cancers
AU2020281923A1 (en) 2019-05-31 2022-01-06 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as P2X3 inhibitors
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
ES2973832T3 (es) 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
MY209360A (en) 2019-10-31 2025-07-03 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
PL4081305T3 (pl) 2019-12-24 2025-02-10 Carna Biosciences, Inc. Związki modulujące kinazę diacyloglicerolową
EP4103285A2 (en) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
EP4126231A1 (en) 2020-03-30 2023-02-08 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
PL4126862T3 (pl) * 2020-04-02 2025-09-08 Gilead Sciences, Inc. Sposób wytwarzania związku będącego inhibitorem cot
CA3181922A1 (en) 2020-05-01 2021-11-04 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
JP7686086B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TWI857377B (zh) 2021-10-28 2024-10-01 美商基利科學股份有限公司 嗒-3(2h)-酮衍生物
MX2024005066A (es) 2021-10-29 2024-05-24 Gilead Sciences Inc Compuestos de cd73.
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
PE20242225A1 (es) 2022-03-17 2024-11-19 Gilead Sciences Inc Degradadores de dedos de zinc de la familia ikaros y usos de estos
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
CA3260083A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. CD73 COMPOUNDS
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US20250100998A1 (en) 2023-07-26 2025-03-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
SG145744A1 (en) 2003-08-19 2008-09-29 Wyeth Corp Process for the preparation of 4-amino-3- quinolinecarbonitriles
EP1881981A1 (en) 2005-05-18 2008-01-30 Wyeth 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
JP2008540656A (ja) * 2005-05-18 2008-11-20 ワイス Ｔｐｌ２キナーゼの３−シアノキノリン阻害物質ならびにそれを製造および使用する方法
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
US20130059851A1 (en) 2010-03-09 2013-03-07 Dana-Farber Cancer Institute, Inc. Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy
IN2015DN03795A (es) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
US9815818B2 (en) 2015-07-06 2017-11-14 Gilead Sciences, Inc. Cot modulators and methods of use thereof
EP3456717B1 (en) 2015-07-06 2021-03-17 Gilead Sciences, Inc. 4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
EP3478674B1 (en) 2016-06-30 2020-05-13 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof

Also Published As

Publication number Publication date
JP2020073614A (ja) 2020-05-14
AU2017289158C1 (en) 2020-07-23
US10059695B2 (en) 2018-08-28
TWI644910B (zh) 2018-12-21
NZ749172A (en) 2020-07-31
AU2017289158A1 (en) 2019-01-03
ES2800339T3 (es) 2020-12-29
TWI680126B (zh) 2019-12-21
EP3478674B1 (en) 2020-05-13
US20190016705A1 (en) 2019-01-17
CA3029457A1 (en) 2018-01-04
EP3478674A1 (en) 2019-05-08
AU2017289158B2 (en) 2019-12-19
TW201805281A (zh) 2018-02-16
JP2019519580A (ja) 2019-07-11
US10577352B2 (en) 2020-03-03
JP6776378B2 (ja) 2020-10-28
TW201920151A (zh) 2019-06-01
WO2018005435A1 (en) 2018-01-04
US20180002316A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
AR108926A1 (es) Moduladores de cot y sus métodos de uso
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR116993A2 (es) Compuestos heterociclos bicíclicos y sus usos en terapia
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR106472A1 (es) Inhibidores de acc y usos de los mismos
AR089182A1 (es) Derivados de aminopirimidina como moduladores de lrrk2
AR108812A1 (es) Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo
AR119138A1 (es) Moduladores de cot y métodos de uso de los mismos
AR100315A1 (es) Compuestos de piridina sustituida que tienen acción herbicida
AR096684A1 (es) Compuestos para tratar atrofia muscular espinal
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
AR102492A1 (es) Cromanos sustituidos y métodos para su uso
AR127404A1 (es) Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR109709A1 (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR090293A1 (es) Inhibidores de quinasa a base de arileter
AR110298A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR102258A1 (es) Compuestos de quinolina y quinazolina
AR109735A1 (es) Método para la síntesis de derivado de 3-fenil-2,3,4,8,9,10-hexahidropirano[2,3-f]cromeno e isómero óptico del mismo
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
MX2018014944A (es) Tratamiento para la enfermedad de parkinson.

Legal Events

Date Code Title Description
FB Suspension of granting procedure